公开(公告)号：US20200268754A1

公开(公告)日：2020-08-27

申请号：US16819341

申请日：2020-03-16

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Margaret MOLINE ,  Gina PASTINO ,  Yurie AKIMOTO ,  Yasuhiro ZAIMA ,  Nobuya SUZUKI ,  Nobuo YOSHIDA

IPC: A61K31/506 ,  A61K9/00 ,  A61K9/20 ,  A61K9/48

Abstract: In the present invention, compound such as (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl) cyclopropanecarboxamide have been found to be potent orexin receptor antagonists, and may be useful in the treatment of sleep disorders such as insomnia, as well as for other therapeutic uses.

公开(公告)号：US20170252342A1

公开(公告)日：2017-09-07

申请号：US15519676

申请日：2015-10-21

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Margaret MOLINE ,  Gina PASTINO ,  Yurie AKIMOTO ,  Yasuhiro ZAIMA ,  Nobuya SUZUKI ,  Nobuo YOSHIDA

IPC: A61K31/506 ,  A61K9/48 ,  A61K9/20 ,  A61K9/00

CPC classification number: A61K31/506 ,  A61K9/0053 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/48 ,  A61K9/4858 ,  A61K9/4866

Abstract: In the present invention, compound such as (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl) cyclopropanecarboxamide have been found to be potent orexin receptor antagonists, and may be useful in the treatment of sleep disorders such as insomnia, as well as for other therapeutic uses.

公开(公告)号：US20230103250A1

公开(公告)日：2023-03-30

申请号：US17787752

申请日：2021-01-14

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Taichi ABE ,  Yusuke AYATA ,  Nobuya SUZUKI ,  Yurie AKIMOTO ,  Futoshi SHIKATA ,  Yasuhiro Zaima ,  Nobuo YOSHIDA

IPC: A61K31/506 ,  A61K9/20 ,  A61K9/16

Abstract: There is provided a pharmaceutical composition comprising lemborexant exhibiting a favorable dissolution profile by using a granular material having a 90% cumulative diameter (D90) of 64 μm or less as a lemborexant active pharmaceutical ingredient.

公开(公告)号：US20190201399A1

公开(公告)日：2019-07-04

申请号：US16255116

申请日：2019-01-23

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Margaret MOLINE ,  Gina PASTINO ,  Yurie AKIMOTO ,  Yasuhiro ZAIMA ,  Nobuya SUZUKI ,  Nobuo YOSHIDA

IPC: A61K31/506 ,  A61K9/48 ,  A61K9/00 ,  A61K9/20

Abstract: In the present invention, compound such as (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide have been found to be potent orexin receptor antagonists, and may be useful in the treatment of sleep disorders such as insomnia, as well as for other therapeutic uses.